Pharmas have increased their interest in digital capabilities, especially for clinical trials and gathering real world evidence, as well as for consumer applications.
Embedding digital into pharma's DNA
Augmenting R&D with artificial intelligence
Value-based healthcare and Value Labs
Life sciences dealmaking expected to continue
Australia’s diverted profits tax
Cracking the engaged aging code through technology
Global Corporate Divestment Study: Life sciences
The 2017 outlook for life sciences
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.
We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.
Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.
Take a closer look:
- The new mandatory health insurance scheme: taking stock one year after the introduction (Insurance newsletter – February 2015)
- Ripe for investment: the Indonesian health care industry post introduction of universal health coverage
- Progressions 2012: health care everywhere
- Progressions 2011: Pharma 3.0
- Cash on prescription 2012: pharmaceutical companies and working capital
- Cash on prescription 2011: pharmaceutical companies and working capital
Request or call a meeting
If you have a specific service need or inquiry, please contact our Business Development Program Office team.
Tel: +62 21 5289 5672
Tel: +62 21 5289 5136
Tel: +62 21 5289 5138
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.
Conversations in health care, a special edition, features interviews with health care leaders from around the world.